China Contract Research Organization (CRO) Industry Report, 2015-2018
In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of 25.9%. With so many favorable policies, especially when a number of well-known proprietary drugs are about to expire, China’s CRO market size is expected to continue to grow by around 20% in the years ahead, to an estimated RMB 83.2 billion by 2018.
At present, some European and American CRO enterprises represented by Quintiles and Covance have penetrated the Chinese market by establishing branches or through acquisition and cooperation. These foreign giants, which occupy the majority of China’s CRO market share, are driving the industry to develop toward standardization.
There are more than 500 Chinese CRO enterprises, such as WuXi AppTec, Tigermed Consulting, Boji Medical Biotechnological, and HD Biosciences, which have a relatively large scale and develop very well. In 2014, WuXi AppTec represented a 9.69% market share while Tigermed Consulting and Boji Medical Biotechnological accounted for 1.47% and 0.34%, respectively.
As a leader in China’s CRO industry, WuXi AppTec posted revenue of RMB4.1266 billion (equivalent to USD674.3 million) in 2014, up 16.6% from a year earlier. In recent years, the company has seen rapid expansion by acquiring AppTec, ABGENT, Shanghai Medkey Med-Tech Development Co., and NextCODE Health.
Tigermed Consulting is a CRO company that specializes in the services related to clinical trials and clinical research. In 2014, the company recorded RMB624.6 million in revenue, up as high as 85.6%. In August 2012, the company completed its IPO, and then continuously strengthened its competitiveness through M&A and investment in subsidiaries. During 2013-2014, Tigermed Consulting founded Fantastic Bioimaging, Shanghai Tigermed Consulting Co., Hangzhou Talent MedCinsultant, and Tigermed-IntelliPV Ltd., and purchased BDM and Frontage Labs. In 2015, the company announced a proposed acquisition of Beiyi Renzhi (Beijing) Medical Technology Development Co. and DreamCIS Inc, a South Korean company.
Boji Medical Biotechnological, a comprehensive CRO company, was publicly traded on GEM of Shenzhen Stock Exchange in April 2015. As of the end of 2014, it had provided an accumulated more than 400 clinical research services and over 200 preclinical research services. In recent years, it has begun to focus on international expansion, successively undertaking the service projects of some overseas companies including Sweden’s Astrom Research International and South Korea’s Hyundai Pharmaceutical.
China Contract Research Organization (CRO) Industry Report, 2015-2018 is mainly all about the following:
At present, some European and American CRO enterprises represented by Quintiles and Covance have penetrated the Chinese market by establishing branches or through acquisition and cooperation. These foreign giants, which occupy the majority of China’s CRO market share, are driving the industry to develop toward standardization.
There are more than 500 Chinese CRO enterprises, such as WuXi AppTec, Tigermed Consulting, Boji Medical Biotechnological, and HD Biosciences, which have a relatively large scale and develop very well. In 2014, WuXi AppTec represented a 9.69% market share while Tigermed Consulting and Boji Medical Biotechnological accounted for 1.47% and 0.34%, respectively.
As a leader in China’s CRO industry, WuXi AppTec posted revenue of RMB4.1266 billion (equivalent to USD674.3 million) in 2014, up 16.6% from a year earlier. In recent years, the company has seen rapid expansion by acquiring AppTec, ABGENT, Shanghai Medkey Med-Tech Development Co., and NextCODE Health.
Tigermed Consulting is a CRO company that specializes in the services related to clinical trials and clinical research. In 2014, the company recorded RMB624.6 million in revenue, up as high as 85.6%. In August 2012, the company completed its IPO, and then continuously strengthened its competitiveness through M&A and investment in subsidiaries. During 2013-2014, Tigermed Consulting founded Fantastic Bioimaging, Shanghai Tigermed Consulting Co., Hangzhou Talent MedCinsultant, and Tigermed-IntelliPV Ltd., and purchased BDM and Frontage Labs. In 2015, the company announced a proposed acquisition of Beiyi Renzhi (Beijing) Medical Technology Development Co. and DreamCIS Inc, a South Korean company.
Boji Medical Biotechnological, a comprehensive CRO company, was publicly traded on GEM of Shenzhen Stock Exchange in April 2015. As of the end of 2014, it had provided an accumulated more than 400 clinical research services and over 200 preclinical research services. In recent years, it has begun to focus on international expansion, successively undertaking the service projects of some overseas companies including Sweden’s Astrom Research International and South Korea’s Hyundai Pharmaceutical.
China Contract Research Organization (CRO) Industry Report, 2015-2018 is mainly all about the following:
- Status quo, related policies, market size, competitive landscape, development trends, etc. of China’s CRO industry;
- Development environment of China’s CRO industry, including international environment, industry environment, and regional market;
- Operation, R&D and investment, development in China, etc. of 5 global and 13 Chinese CRO companies;
- Development prediction of China’s CRO industry as well as operation of major enterprises.
1. OVERVIEW OF PHARMACEUTICAL OUTSOURCING
1.1 Definition
1.2 Classification
1.3 CRO
2. OVERVIEW OF CHINA CRO MARKET
2.1 Status Quo
2.2 Related Policies
2.3 Market Size
2.4 Competitive Landscape
2.5 Development Trends
2.5.1 Industrial Chain Improvement
2.5.2 Internationalization of Qualification Certification Standard
2.5.3 Development Driven by Technical Innovation
3. DEVELOPMENT ENVIRONMENT OF CHINA CRO INDUSTRY
3.1 International Environment
3.1.1 Development History
3.1.2 Development Status
3.1.3 Major Countries and Regions
3.2 Industry Environment
3.3 Regional Market
3.3.1 Beijing
3.3.2 Shanghai
3.3.3 Chengdu
4. KEY CHINESE CRO PLAYERS
4.1 Wuxi AppTec
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Investment and Development
4.1.6 Forecast and Outlook
4.2 Hangzhou Tigermed Consulting Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Forecast and Outlook
4.3 Guangzhou Boji Medical Biotechnological Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Forecast and Outlook
4.4 ShangPharma Corp
4.4.1 Profile
4.4.2 Operation
4.4.3 Gross Margin
4.5 China Medical Technologies Inc.
4.5.1 Profile
4.5.2 Operation
4.5.3 Gross Margin
4.5.4 Development
4.6 Asymchem
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Forecast and Outlook
4.7 HD Biosciences
4.7.1 Profile
4.7.2 Operation
4.7.3 Development
4.8 Porton
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D and Investment
4.8.6 Forecast and Outlook
4.9 Others
4.9.1 Shanghai Mediclon Inc.
4.9.2 Sundia MediTech Company Ltd.
4.9.3 Guangzhou Yushi Medicinal Technology Co., Ltd.
4.9.4 JOINN Laboratories (Beijing)
5. KEY FOREIGN CRO COMPANIES
5.1 Covance
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 Development in China
5.2 Parexel
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Development in China
5.3 Quintiles
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Development in China
5.4 Charles River
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Development in China
5.5 PPD
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Development in China
6. DEVELOPMENT AND OUTLOOK
6.1 Industry Development Prediction
6.2 Operation of Major CRO Companies
6.2.1 Revenue
6.2.2 Net Income
6.2.3 Gross Margin
1.1 Definition
1.2 Classification
1.3 CRO
2. OVERVIEW OF CHINA CRO MARKET
2.1 Status Quo
2.2 Related Policies
2.3 Market Size
2.4 Competitive Landscape
2.5 Development Trends
2.5.1 Industrial Chain Improvement
2.5.2 Internationalization of Qualification Certification Standard
2.5.3 Development Driven by Technical Innovation
3. DEVELOPMENT ENVIRONMENT OF CHINA CRO INDUSTRY
3.1 International Environment
3.1.1 Development History
3.1.2 Development Status
3.1.3 Major Countries and Regions
3.2 Industry Environment
3.3 Regional Market
3.3.1 Beijing
3.3.2 Shanghai
3.3.3 Chengdu
4. KEY CHINESE CRO PLAYERS
4.1 Wuxi AppTec
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Investment and Development
4.1.6 Forecast and Outlook
4.2 Hangzhou Tigermed Consulting Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Forecast and Outlook
4.3 Guangzhou Boji Medical Biotechnological Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Forecast and Outlook
4.4 ShangPharma Corp
4.4.1 Profile
4.4.2 Operation
4.4.3 Gross Margin
4.5 China Medical Technologies Inc.
4.5.1 Profile
4.5.2 Operation
4.5.3 Gross Margin
4.5.4 Development
4.6 Asymchem
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Forecast and Outlook
4.7 HD Biosciences
4.7.1 Profile
4.7.2 Operation
4.7.3 Development
4.8 Porton
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D and Investment
4.8.6 Forecast and Outlook
4.9 Others
4.9.1 Shanghai Mediclon Inc.
4.9.2 Sundia MediTech Company Ltd.
4.9.3 Guangzhou Yushi Medicinal Technology Co., Ltd.
4.9.4 JOINN Laboratories (Beijing)
5. KEY FOREIGN CRO COMPANIES
5.1 Covance
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 Development in China
5.2 Parexel
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Development in China
5.3 Quintiles
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Development in China
5.4 Charles River
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Development in China
5.5 PPD
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Development in China
6. DEVELOPMENT AND OUTLOOK
6.1 Industry Development Prediction
6.2 Operation of Major CRO Companies
6.2.1 Revenue
6.2.2 Net Income
6.2.3 Gross Margin
SELECTED CHARTS
Classification of Pharmaceutical Outsourcing
R&D Process of New Drugs
Research Application of New Drugs in China, 2010-2014
China’s Policies on CRO Industry, 2001-2015
Market Size and YoY Growth of China’s CRO Industry, 2007-2014
Layout of Major Global CRO Companies in Asia
Distribution of Major Foreign CRO Companies in China
Business Mode of Chinese CRO Companies
Market Share of China’s CRO Industry by Company, 2014
R&D Costs of International Pharmaceutical Giants, 2009-2014
Sales of Global Top 10 Pharmaceutical Companies, 2014
Market Size and YoY Growth of Global CRO Industry, 2007-2014
Market Share of Global CRO Industry by Region, 2014
Revenue and Total Profit of Chinese Pharmaceutical Enterprises, 2010-2014
Revenue of Chinese Pharmaceutical Enterprises by Province, 2014
Major Regions and Characteristics of China’s Pharmaceutical Industry,
Capital Transactions and Disclosed Amount of Biomedical Industry in Beijing, 2014
Revenue and YoY Growth of Enterprises under ABO Alliance, 2007-2014
Initiators of Zhongguancun CRO Alliance (Listed Randomly)
Platform Advantages of Zhangjiang Drug Valley
List of Major CRO Companies in Zhangjiang Drug Valley
Business Areas Distribution of WuXi AppTec
WuXi AppTec’s Revenue and Net Income, 2010-2015
WuXi AppTec’s Revenue Breakdown by Business, 2010-2015
WuXi AppTec’s Revenue Structure by Business, 2010-2015
WuXi AppTec’s Revenue Breakdown by Region, 2010-2014
WuXi AppTec’s Revenue Structure by Region, 2010-2014
WuXi AppTec’s Gross Margin, 2010-2015
WuXi AppTec’s Gross Margin by Business, 2010-2015
WuXi AppTec’s Revenue and Net Income, 2013-2018E
Revenue and Net Income of Tigermed Consulting, 2010-2015
Tigermed Consulting’s Revenue Breakdown by Business, 2013-2014
Tigermed Consulting’s Revenue Structure by Business, 2013-2014
Tigermed Consulting’s Revenue Breakdown by Region, 2010-2014
Tigermed Consulting’s Revenue Structure by Region, 2010-2014
Tigermed Consulting’s Gross Margin, 2010-2015
Tigermed Consulting’s Gross Margin by Region, 2010-2014
Tigermed Consulting’s R&D Costs and % of Total Revenue, 2011-2014
Tigermed Consulting’s Revenue and Net Income, 2014-2018E
Boji Medical Biotechnological’s Revenue and Net Income, 2011-2015
Boji Medical Biotechnological’s Revenue Breakdown by Business, 2011-2014
Boji Medical Biotechnological’s Revenue Structure by Business, 2011-2014
Boji Medical Biotechnological’s Revenue Breakdown by Region, 2011-2014
Boji Medical Biotechnological’s Gross Margin, 2011-2015
Boji Medical Biotechnological’s Gross Margin by Business, 2011-2014
R&D Costs and % of Total Revenue of Boji Medical Biotechnological, 2011-2014
Major Service Content of Boji Medical Biotechnological
Boji Medical Biotechnological’s Subsidiaries and Their Main Business
Fundraising Projects of Boji Medical Biotechnological
Revenue and Net Income of Boji Medical Biotechnological, 2014-2018E
ShangPharma Corp’s Organization Structure
ShangPharma Corp’s Revenue and Net Income, 2009-2014
ShangPharma Corp’s Gross Margin, 2009-2014
Revenue and Net Income of China Medical Technologies, 2010-2015
Gross Margin of China Medical Technologies, 2010-2015
Asymchem’s Revenue and Net Income, 2011-2014
Asymchem’s Revenue Breakdown by Business, 2011-2014
Asymchem’s Revenue Structure by Business, 2011-2014
Asymchem’s Gross Margin, 2011-2014
Asymchem’s R&D Costs and % of Total Revenue, 2011-2013
Asymchem’s Major Subsidiaries and Offices
Asymchem’s Orders by Type, 2011-2013
Asymchem’s Proposed Fundraising Project through IPO, May 2014
Asymchem’s Revenue and Net Income, 2013-2018E
HD Biosciences’ Revenue and Net Income, 2013-2014
HD Biosciences’ Total Assets and Liabilities, 2013-2014
Porton’s Revenue and Net Income, 2010-2015
Porton’s Revenue Breakdown by Region, 2010-2015
Porton’s Revenue Structure by Region, 2010-2014
Porton’s Gross Margin, 2010-2015
Porton’s Gross Margin by Region, 2010-2014
Porton’s R&D Costs and % of Total Revenue, 2012-2014
Porton’s Fundraising Project
Porton’s Revenue and Net Income, 2014-2018E
Covance’s Revenue and Net Income, 2009-2014
Covance’s Revenue Breakdown by Business, 2009-2014
Covance’s Revenue Structure by Business, 2009-2014
Covance’s Revenue Breakdown by Region, 2011-2014
Covance’s Revenue Structure by Region, 2011-2014
Covance’s Gross Margin, 2009-2014
Parexel’s Revenue and Net Income, 2009-2014
Parexel’s Revenue Breakdown by Business, 2009-2014
Parexel’s Revenue Structure by Business, 2009-2014
Parexel’s Revenue Breakdown by Region, 2009-2014
Parexel’s Revenue Structure by Region, 2009-2014
Quintiles’ Revenue and Net Income, 2010-2015
Quintiles’ Revenue Breakdown by Business, 2010-2015
Quintiles’ Revenue Structure by Business, 2010-2015
Quintiles’ Revenue Breakdown by Region, 2010-2015
Quintiles’ Revenue Structure by Region, 2010-2014
Quintiles’ Gross Margin, 2010-2015
Charles River’s Revenue and Net Income, 2010-2015
Charles River’s Revenue Breakdown by Business, 2013-2015
Charles River’s Revenue Structure by Business, 2013-2015
Charles River’s Revenue Breakdown by Region, 2011-2014
Charles River’s Revenue Structure by Region, 2011-2014
Charles River’s Gross Margin, 2010-2015
PPD’s Revenue and Net Income, 2008-2011
PPD’s Revenue Breakdown by Business, 2008-2011
PPD’s Revenue Structure by Business, 2008-2011
Global Proprietary Drugs Having Expired or to Expire, 2014-2016
Market Share and YoY Growth Rate of China’s CRO Industry, 2014-2018E
Revenue of Major Chinese CRO Companies, 2010-2014
Net Income of Major Chinese CRO Companies, 2010-2014
Net Profit Margin of Major Chinese CRO Companies, 2010-2014
Gross Margin of Major Chinese CRO Companies, 2010-2014
Classification of Pharmaceutical Outsourcing
R&D Process of New Drugs
Research Application of New Drugs in China, 2010-2014
China’s Policies on CRO Industry, 2001-2015
Market Size and YoY Growth of China’s CRO Industry, 2007-2014
Layout of Major Global CRO Companies in Asia
Distribution of Major Foreign CRO Companies in China
Business Mode of Chinese CRO Companies
Market Share of China’s CRO Industry by Company, 2014
R&D Costs of International Pharmaceutical Giants, 2009-2014
Sales of Global Top 10 Pharmaceutical Companies, 2014
Market Size and YoY Growth of Global CRO Industry, 2007-2014
Market Share of Global CRO Industry by Region, 2014
Revenue and Total Profit of Chinese Pharmaceutical Enterprises, 2010-2014
Revenue of Chinese Pharmaceutical Enterprises by Province, 2014
Major Regions and Characteristics of China’s Pharmaceutical Industry,
Capital Transactions and Disclosed Amount of Biomedical Industry in Beijing, 2014
Revenue and YoY Growth of Enterprises under ABO Alliance, 2007-2014
Initiators of Zhongguancun CRO Alliance (Listed Randomly)
Platform Advantages of Zhangjiang Drug Valley
List of Major CRO Companies in Zhangjiang Drug Valley
Business Areas Distribution of WuXi AppTec
WuXi AppTec’s Revenue and Net Income, 2010-2015
WuXi AppTec’s Revenue Breakdown by Business, 2010-2015
WuXi AppTec’s Revenue Structure by Business, 2010-2015
WuXi AppTec’s Revenue Breakdown by Region, 2010-2014
WuXi AppTec’s Revenue Structure by Region, 2010-2014
WuXi AppTec’s Gross Margin, 2010-2015
WuXi AppTec’s Gross Margin by Business, 2010-2015
WuXi AppTec’s Revenue and Net Income, 2013-2018E
Revenue and Net Income of Tigermed Consulting, 2010-2015
Tigermed Consulting’s Revenue Breakdown by Business, 2013-2014
Tigermed Consulting’s Revenue Structure by Business, 2013-2014
Tigermed Consulting’s Revenue Breakdown by Region, 2010-2014
Tigermed Consulting’s Revenue Structure by Region, 2010-2014
Tigermed Consulting’s Gross Margin, 2010-2015
Tigermed Consulting’s Gross Margin by Region, 2010-2014
Tigermed Consulting’s R&D Costs and % of Total Revenue, 2011-2014
Tigermed Consulting’s Revenue and Net Income, 2014-2018E
Boji Medical Biotechnological’s Revenue and Net Income, 2011-2015
Boji Medical Biotechnological’s Revenue Breakdown by Business, 2011-2014
Boji Medical Biotechnological’s Revenue Structure by Business, 2011-2014
Boji Medical Biotechnological’s Revenue Breakdown by Region, 2011-2014
Boji Medical Biotechnological’s Gross Margin, 2011-2015
Boji Medical Biotechnological’s Gross Margin by Business, 2011-2014
R&D Costs and % of Total Revenue of Boji Medical Biotechnological, 2011-2014
Major Service Content of Boji Medical Biotechnological
Boji Medical Biotechnological’s Subsidiaries and Their Main Business
Fundraising Projects of Boji Medical Biotechnological
Revenue and Net Income of Boji Medical Biotechnological, 2014-2018E
ShangPharma Corp’s Organization Structure
ShangPharma Corp’s Revenue and Net Income, 2009-2014
ShangPharma Corp’s Gross Margin, 2009-2014
Revenue and Net Income of China Medical Technologies, 2010-2015
Gross Margin of China Medical Technologies, 2010-2015
Asymchem’s Revenue and Net Income, 2011-2014
Asymchem’s Revenue Breakdown by Business, 2011-2014
Asymchem’s Revenue Structure by Business, 2011-2014
Asymchem’s Gross Margin, 2011-2014
Asymchem’s R&D Costs and % of Total Revenue, 2011-2013
Asymchem’s Major Subsidiaries and Offices
Asymchem’s Orders by Type, 2011-2013
Asymchem’s Proposed Fundraising Project through IPO, May 2014
Asymchem’s Revenue and Net Income, 2013-2018E
HD Biosciences’ Revenue and Net Income, 2013-2014
HD Biosciences’ Total Assets and Liabilities, 2013-2014
Porton’s Revenue and Net Income, 2010-2015
Porton’s Revenue Breakdown by Region, 2010-2015
Porton’s Revenue Structure by Region, 2010-2014
Porton’s Gross Margin, 2010-2015
Porton’s Gross Margin by Region, 2010-2014
Porton’s R&D Costs and % of Total Revenue, 2012-2014
Porton’s Fundraising Project
Porton’s Revenue and Net Income, 2014-2018E
Covance’s Revenue and Net Income, 2009-2014
Covance’s Revenue Breakdown by Business, 2009-2014
Covance’s Revenue Structure by Business, 2009-2014
Covance’s Revenue Breakdown by Region, 2011-2014
Covance’s Revenue Structure by Region, 2011-2014
Covance’s Gross Margin, 2009-2014
Parexel’s Revenue and Net Income, 2009-2014
Parexel’s Revenue Breakdown by Business, 2009-2014
Parexel’s Revenue Structure by Business, 2009-2014
Parexel’s Revenue Breakdown by Region, 2009-2014
Parexel’s Revenue Structure by Region, 2009-2014
Quintiles’ Revenue and Net Income, 2010-2015
Quintiles’ Revenue Breakdown by Business, 2010-2015
Quintiles’ Revenue Structure by Business, 2010-2015
Quintiles’ Revenue Breakdown by Region, 2010-2015
Quintiles’ Revenue Structure by Region, 2010-2014
Quintiles’ Gross Margin, 2010-2015
Charles River’s Revenue and Net Income, 2010-2015
Charles River’s Revenue Breakdown by Business, 2013-2015
Charles River’s Revenue Structure by Business, 2013-2015
Charles River’s Revenue Breakdown by Region, 2011-2014
Charles River’s Revenue Structure by Region, 2011-2014
Charles River’s Gross Margin, 2010-2015
PPD’s Revenue and Net Income, 2008-2011
PPD’s Revenue Breakdown by Business, 2008-2011
PPD’s Revenue Structure by Business, 2008-2011
Global Proprietary Drugs Having Expired or to Expire, 2014-2016
Market Share and YoY Growth Rate of China’s CRO Industry, 2014-2018E
Revenue of Major Chinese CRO Companies, 2010-2014
Net Income of Major Chinese CRO Companies, 2010-2014
Net Profit Margin of Major Chinese CRO Companies, 2010-2014
Gross Margin of Major Chinese CRO Companies, 2010-2014
